Pfizer Inc has his investigation sildenafil citrate (Viagra) ended as a treatment for female genital excitation disorder (FSAD), after several big studies showed the efficacy not unambiguously. The enterprise immediately be closed FSAD research program, which is begun in 1996.
The researchers found out, that the men an average of two risk factors, as hypertension and diabetes had. All together 54 percent of the men answered erectile function of the guests, although the response rate with the old person from sildenafil, with a middle increase of 5.7 in her international index of erectile the function. The incidence of side effects between the different Comparable what age groups.
“Although we are disappointed that the FSAD program any more successfully, this is not the kind of the development of drugs,” to Cirques Katen, president of Pfizer Worldwide Pharmaceuticals, said in an enterprise give a holiday. “We make considerable financial investments, marshal of the talents of our best scientists and clinicians, and spend years with the study possible treatments only to find out, they did not the demands for the licensing.”
“From these data sildenafil is an effective medicine with older men, however, had a lower efficacy rate with increasing old person, above all with men at the old person to more than 80 years,” Mulhall and colleagues close. “The incidence of side effects was as in the general population under sildenafil, without difference in the undesirable events with the different age groups.”
To placebo-controlled studies with about 3.000 women found sildenafil to be sure, but to the efficacy data were not unequivocal, reported the enterprise. A study, carried out in Canada and reports in the British journal for gynecology and obstetrics (in 2003, 110:1014-24) to the end that sildenafil, 50 mg, FSAD or do not improve orgasm affected in the general one, although can profit from it a small subset women with a low vaginal pulse amplitude-answer.
Pfizer said, it also becomes, furthermore in the research of women genital health checks to invest and alternative treatment possibilities gives.
“Innovative On account of the research of Pfizer, now we have involved a better understanding of the biochemical and physiological factors with female genital function,” said Joe Feczko, MD, president of Worldwide Development with Pfizer, “in addition, we have created and to allow doctors to identify validated instruments to measure more exactly to patients with FSAD subtypes and the effect from potential uses. “

